CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Donepezil, 5 mg daily +1 moredrug
Likely dose
Donepezil, 5 mg dailyfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00467389
NCT00467389Phase 2Completed
CompareCT.gov

Donepezil Effects on Cocaine Craving and Pharmacokinetics

US Department of Veterans Affairs·interventional·Posted Apr 30, 2007·Updated Jun 9, 2014

In Brief

A Phase 2 clinical trial evaluating Donepezil, 5 mg daily and Oral Placebo for Cocaine Abuse and Dependence. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the safety of intravenous cocaine in subjects receiving oral donepezil.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Abuse and Dependence
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 30, 2007
Enrollment StartFeb 1, 2007
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.2 years ago

Interventions

Donepezil, 5 mg dailydrug

This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.

Oral Placeboother

Inactive Comparator with Similar Appearance to Active Medication